
|Videos|December 4, 2020
Dr. Surena Matin discusses significance of OLYMPUS trial, Jelmyto
Author(s)Urology Times staff
“[Low-grade upper tract urothelial carcinoma] is fairly uncommon, yet it’s common enough that every urologist comes across it,” says Surena F. Matin, MD.
Advertisement
In this video, Surena F. Matin, MD, discusses the significance of the OLYMPUS trial of mitomycin-containing reverse thermal hydrogel (Jelmyto) for low-grade upper tract urothelial carcinoma and how the treatment addresses an unmet therapeutic need. Final results of the OLYMPUS trial were presented at the 2020 Society of Urologic Oncology annual meeting. Matin is a professor urology at the University of Texas MD Anderson Cancer Center, Houston.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves enfortumab vedotin plus pembrolizumab for MIBC
2
Study suggests tamsulosin deprescribing may be appropriate for select men with BPH
3
Amy E. Krambeck, MD, on choosing between CVAC and FANS for suction-based ureteroscopy
4
Trial launches of actinium (225Ac) rhPSMA-10.1 injection in mCRPC
5













